JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Fulgent Genetics Inc

Gesloten

SectorGezondheidszorg

23.6 0.64

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

23

Max

23.74

Belangrijke statistieken

By Trading Economics

Inkomsten

-7.4M

-19M

Verkoop

8.3M

82M

Winstmarge

-23.539

Werknemers

1,313

EBITDA

-3.5M

-15M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+7.79% upside

Dividenden

By Dow Jones

Volgende Winsten

7 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

181M

730M

Vorige openingsprijs

22.96

Vorige sluitingsprijs

23.6

Nieuwssentiment

By Acuity

50%

50%

163 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Fulgent Genetics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 okt 2025, 20:49 UTC

Winsten

Correction to Thermo Fisher Article on Oct. 22

23 okt 2025, 23:51 UTC

Marktinformatie

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 okt 2025, 23:49 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 okt 2025, 23:49 UTC

Marktinformatie

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 okt 2025, 23:37 UTC

Marktinformatie

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 okt 2025, 22:58 UTC

Marktinformatie

Global Energy Roundup: Market Talk

23 okt 2025, 22:57 UTC

Marktinformatie

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 okt 2025, 22:49 UTC

Acquisities, Fusies, Overnames

How Trump Sparked a New Era of State Capitalism -2-

23 okt 2025, 22:49 UTC

Acquisities, Fusies, Overnames

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 okt 2025, 22:17 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 okt 2025, 21:41 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 okt 2025, 21:05 UTC

Winsten

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 okt 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

23 okt 2025, 20:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

23 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 okt 2025, 20:35 UTC

Winsten

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 okt 2025, 20:28 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 okt 2025, 20:15 UTC

Marktinformatie
Winsten

Global Commodities Roundup: Market Talk

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q Adj EPS $1.71

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q Sales $5.52B

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q EPS $1.67

23 okt 2025, 20:09 UTC

Winsten

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 okt 2025, 20:07 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

23 okt 2025, 20:07 UTC

Marktinformatie
Winsten

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 okt 2025, 20:07 UTC

Winsten

Blackstone Looks to IPOs for Investment Exits -- Update

23 okt 2025, 20:05 UTC

Winsten

Intel 3Q Gross Margin 38.2% >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 okt 2025, 20:04 UTC

Winsten

Intel: 4Q Guidance Excludes Altera >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel Sees 4Q Adj EPS 8c >INTC

Peer Vergelijking

Prijswijziging

Fulgent Genetics Inc Prognose

Koersdoel

By TipRanks

7.79% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25.33 USD  7.79%

Hoogste 30 USD

Laagste 21 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fulgent Genetics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technische score

By Trading Central

17.32 / 19.04Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

163 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
help-icon Live chat